Legacy Investments

These are prior Capital Midwest Fund (CMF) investments that are not representative of CMF's strategy going forward. CMF no longer invests in pre-clinical or clinical-stage companies.

Gemphire Therapeutics.png

IPO - Exited Position

Gemphire Therapeutics was a clinical-stage biopharmaceutical company focused on cardiometabolic disorders, including dyslipidemia and NASH. In December 2019, Gemphire Therapeutics merged with NeuroBo Pharmaceuticals (NASDAQ: NRBO), which is the surviving entity.

Ocuphire Pharma.png

Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on a variety of ophthalmic disorders. The company's lead drug candidate is a once-daily eye drop, Nyxol®, to treat multiple front-of-the-eye disorders, including night vision disturbances, pharmacologically-induced mydriasis, and presbyopia.

PreEmptive Meds.png

PMI’s products represent viable options for preempting disease or assisting in medical treatment and are supported by meaningful clinical data.

PrevaCept Infection Control.png

PrevaCept Infection Control

[fka Great Lakes Pharmaceuticals]

PrevaCept Infection Control is a clinical-stage company focused on development and commercialization of products designed to prevent infections associated with indwelling catheters.

Rapid Diagnostek.png


Rapid Diagnostek developed a patented, point-of-care, biosensor-based platform appropriate for detecting proteins, bacteria, viruses, and other substances contained in liquid samples. Rapid Diagnostek was acquired by Qorvo in 2016.

SeaStar Medical.png

SeaStar Medical

[fka CytoPherx]

SeaStar Medical's products focus on treating acute, inflammatory-driven conditions.

Sierra Oncology.png

Sierra Oncology


[fka ProNAi Therapeutics (NASDAQ: DNAI)]


Sierra Oncology is a biotechnology company developing therapeutics for the treatment of hematology and oncology.



TPI focused on making biosimilar medications affordable by developing a proprietary, single-use technology platform, MayaBio®, to build a strong pipeline of biosimilar candidates. TPI renamed to Adello Biologics in 2016 and was acquired by Kashiv BioSciences in 2019.


10556 N Port Washington Rd
Ste 201
Mequon, WI 53092

(414) 453-4488